Lupus & antiphospholipid syndrome
A novel nomogram based on the identification of soluble TREM2 (sTREM2) as a biomarker to predict developing neuropsychiatric systemic lupus erythematosus in lupus patients
Authors' conclusion
sTREM2 presents as a promising biomarker for NPSLE diagnosis. The nomogram that includes serum sTREM2 level as one of the predictors is effective for distinguishing NPSLE from non-NPSLE patients.
Study context
- Population
- SLE patients with and without neuropsychiatric systemic lupus erythematosus (NPSLE)3 matched controls per NPSLE patient
- Comparison
- NPSLE vs matched non-NPSLE SLE controls
- NPSLEn = 80
- Outcome
- Diagnostic capability of sTREM2 and a nomogram to predict development of NPSLE among SLE patients
Methodological detailscase-control (three matched non-NPSLE SLE controls per NPSLE patient), bioinformatics analysis, training and validation sets, Boruta algorithm, nomogram
- Case-control (three matched non-NPSLE SLE controls per NPSLE patient)
- Bioinformatics analysis
- Training and validation sets
- Boruta algorithm
- Nomogram
Performance
As reported in the abstract
- sTREM2 levels notably elevated in both serum and cerebrospinal fluid (CSF) of NPSLE vs non-NPSLE controls
- Serum TREM2 concentrations correlated with NPSLE severity and neuropsychiatric state
- Significant predictors for NPSLE: higher SLE Disease Activity Index (SLEDAI), increased systemic lupus international collaborating clinics (SLICC)/ACR DI, prolonged activated partial thromboplastin time (APTT), higher serum B cells, elevated serum sTREM2
Original publication
A novel nomogram based on the identification of sTREM2 as a biomarker to predict developing neuropsychiatric systemic lupus erythematosus in lupus patients. Clin Exp Rheumatol. Published 2 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →